Edgewise Completed Phase 2 CIRRUS-HCM Parts B And C, Reports Favorable Interim Safety From Part D

Edgewise Therapeutics reported completion of Parts B and C of its Phase 2 CIRRUS-HCM trial of EDG-7500 with positive efficacy signals (dose-dependent improvements in NT-proBNP, KCCQ scores, NYHA class and LVOT gradients in obstructive HCM; NT-proBNP reductions and diastolic trends in non-obstructive HCM) and favorable interim safety from ongoing Part D (no meaningful LVEF reductions and no atrial fibrillation on continuous monitoring). The company reiterated a full 12-week Part D readout is expected in Q2 2026 and plans to initiate Phase 3 by year-end; EWTX traded pre-market at $22.75, up 4.62%, within a 52-week range of $10.60–$30.48.

Analysis

Market structure: A clinically differentiated, systolic-function-preserving oral HCM drug (EDG-7500) would directly benefit Edgewise (EWTX) and incumbents that partner/licence it, expand the treatable patient pool versus current myosin inhibitors (mavacamten/aficamten by BMY/CYTK), and modestly pressure procedural volumes for septal-reduction devices (MDT, BSX) if adoption ramps. Expect elastic demand expansion: if EDG-7500 reduces monitoring burden, addressable treated patient population could grow 2x–3x over 3–5 years versus today, increasing pricing power but inviting payer scrutiny.

Risk assessment: Main tail risks are Phase 3 failure, late safety signals (LVEF decline or arrhythmia) or CMC/manufacturing issues; assign a conservative 30–50% binary failure risk before Phase 3 readout. Timeframes: immediate (days) speculative pop; short-term (next 6–12 months) key catalysts are the 12‑week Part D readout (Q2 2026) and Phase 3 start by YE2026; long-term commercial success depends on label scope, reimbursement and head-to-head data over 2–4 years.

Trade implications: Tactical: small, size-constrained longs and defined-risk option structures are preferred. If elected, build 2–3% net long EWTX now, scale to 4–6% only after a clean Q2 2026 12‑week readout (NT‑proBNP reduction >=25–30% and no LVEF fall >5 ppt). Use LEAP call-spreads to cap downside and amplify upside rather than naked exposure; consider relative short exposure to CYTK to express safety-differentiation.

Contrarian angles: Consensus emphasizes safety upside but may underappreciate commercialization frictions—payers may demand hard outcome data (HF hospitalization/mortality) not just biomarkers, prolonging time-to-market and compressing peak sales. Historical parallels (promising Phase 2 cardio compounds failing in Phase 3) argue for disciplined sizing and event-based tranche adds; implied volatility may be underpriced for multi-stage binary risks, so favor defined-risk option structures over outright leverage.

Key Decisions for Investors

• Establish a tactical 2–3% portfolio long position in EWTX (buy shares) now; set a hard stop-loss at -25% and plan to scale to 4–6% only if Q2 2026 Part D 12‑week readout shows NT‑proBNP reduction >=25–30% and no LVEF decline >5 percentage points.
• Implement a defined-risk options play: buy the EWTX Jan 2027 25/40 call spread (size = ~50% of the cash position) to cap premium while capturing upside to Phase 3 start; close half at +60% gain and remainder at +150% or by Dec 2026 if not earlier.
• Enter a pair trade: long EWTX (as above) and short Cytokinetics (CYTK) equal to 50–75% notional of the EWTX position (size ~0.5–1.0% portfolio) to express safety-differentiation; cover the short if CYTK posts a positive safety update or if EWTX shows any meaningful systolic safety signal.
• Do not increase exposure >3% or purchase vanilla LEAPS until the Q2 2026 readout; if EWTX announces a Big Pharma partnership or non-dilutive financing (> $100M) by Q3 2026, raise allocation to 5% and trim on any single-day move >+50% to lock gains.